CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Sponsor

Vinmec Research Institute of Stem Cell and Gene Technology (Other)

Overall Status

Recruiting

CT.gov ID

NCT06027957

Collaborator

National Institute of Hematology and Blood Transfusion, Vietnam (Other)

Enrollment

Location

Arm

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Brief Summary: Cluster of differentiation 19 (CD19) is expressed on B cells. CD19+ tumor cells in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia can be targeted using T cells expressing CD19-specific chimeric antigen receptor (CAR).
Objective: This study aims to evaluate the safety and efficacy of single-dose anti-CD19 CAR T-cell therapy in the treatment of relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Eligibility: People aged 1 to 60 years with relapsed/refractory CD19+ non-Hodgkin lymphoma and acute lymphoblastic leukemia.
Design: Phase 1 clinical trial, uncontrolled, single dose of CD19 CAR T-cells.

Condition or Disease	Intervention/Treatment	Phase
B-Cell Non Hodgkin Lymphoma B-Cell Acute Lymphoblastic Leukemia	Biological: anti-CD19 CAR T-cells	Phase 1

Detailed Description

Objectives:

Evaluate the frequency and severity of adverse events and serious adverse events (AEs/SAEs) of the therapy.
Evaluate the response rate after CD19 CAR T-cell infusion according to the following criteria:
Proportion of patients with complete response and partial response after CD19 CAR T-cell infusion
Progression-free survival (PFS) after infusion of CD19 CAR T-cells
Event-free survival (EFS) after infusion of CD19 CAR T-cells
Overall survival (OS) after infusion of CD19 CAR T-cells

Study Design

Study Type:

Interventional

Anticipated Enrollment :

16 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Phase I Clinical Trial Evaluating the Safety and Efficacy of Point-of-care CAR-T-cell Therapy in the Treatment of Relapsed/Refractory CD19+ Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Actual Study Start Date :

Aug 2, 2023

Anticipated Primary Completion Date :

Jul 31, 2025

Anticipated Study Completion Date :

Jul 31, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Treatment Regimen Experimental: Treatment Regimen. Leukapheresis to collect white blood cells using Spectra Optia Apheresis system. T cells selection, transduction, and CAR T-cell manufacturing using CliniMACS Prodigy. During this process, T cells will be genetically modified to express CD19 CAR. Lymphodepleting chemotherapy conditioning regimen for 3 days. CAR T-cells targeting CD19 will be infused intravenously at a dose between 1 and 2x10e6 cells/kg for 15-30 minutes. Following the T-cell infusion, patients will stay in the clinic for approximately 21-28 days to monitor toxicity. Outpatient follow-up will take place after 1 month, 3 months, and 6 months after infusion.	Biological: anti-CD19 CAR T-cells For Biological: CD19 CAR T-cells Dose: 1-2.10e6 cells/kg of weight Route: intravenous infusion For Chemotherapy Drug: Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3. Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3. Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after. Other Names: Chemotherapy Drug

Arm

Intervention/Treatment

Experimental: Treatment Regimen

Experimental: Treatment Regimen. Leukapheresis to collect white blood cells using Spectra Optia Apheresis system. T cells selection, transduction, and CAR T-cell manufacturing using CliniMACS Prodigy. During this process, T cells will be genetically modified to express CD19 CAR. Lymphodepleting chemotherapy conditioning regimen for 3 days. CAR T-cells targeting CD19 will be infused intravenously at a dose between 1 and 2x10e6 cells/kg for 15-30 minutes. Following the T-cell infusion, patients will stay in the clinic for approximately 21-28 days to monitor toxicity. Outpatient follow-up will take place after 1 month, 3 months, and 6 months after infusion.

Biological: anti-CD19 CAR T-cells

For Biological: CD19 CAR T-cells Dose: 1-2.10e6 cells/kg of weight Route: intravenous infusion For Chemotherapy Drug: Fludarabine (30 mg/m2/day) given intravenously (IV) on day -5 to -3. Cyclophosphamide 500 mg/m2/day for NHL and 250 mg/m2/day for ALL given IV from day -5 to -3. Mesna 500 mg/m2/day for NHL and 250 mg/m2/day for ALL, divided in three infusions: one day before the cyclophosphamide infusion, and 4 and 8 hours after.

Other Names:

Chemotherapy Drug

Outcome Measures

Primary Outcome Measures

Assessment of the frequency and severity of adverse events and serious adverse events (AEs/SAEs) of the therapy [6 months]
The incidence of adverse events (AEs) and serious adverse events (SAEs) will be recorded and classified according to CTCAE v5 (grade 1-5). CRS and ICANs will be classified using the ASTCT criteria (grade 1-5). These parameters will be used to assess the safety of the therapy.

Secondary Outcome Measures

Proportion of patients with complete response and partial response after CD19 CAR T-cell infusion (%) [Day 30 and day 90 after CAR-T infusion for B-ALL; day 90 after CAR-T infusion for NHL]
Patients with B-ALL will receive bone marrow biopsy assessed on day 30 and day 90 to check blast frequency and MRD. The response will be classified according to NCCN guidelines. Patients with NHL will be examined PET-CT or CT on day 90. The response will be classified according to Cheson guidelines.
Progression-free survival (PFS) (months) [6 months]
PFS is defined as the time from CAR T-cell infusion, until disease progression or death from any cause. Progression is defined as an increase of tumor load, the development of new lesions.
Event-free survival (EFS) (months) [6 months]
EFS is defined as time to treatment failure (including complete remission with incomplete hematologic or platelet recovery), relapse from complete remission, or death from any cause.
Overall survival (OS) (months) [6 months]
EFS is defined as time to death

Eligibility Criteria

Criteria

Ages Eligible for Study:

1 Year to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion criteria:

B-cell acute lymphoblastic leukemia: refractory to two cycles of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation.
B-cell non-Hodgkin lymphoma: refractory to two lines of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation.
Age: From 1 to 60 years old (both males and females)
Adequate organ functions:
Serum creatinine ≤ 1.5 x ULN or eGFR ≥ 60 mL/min/1.73 m2
ALT and AST ≤ 5 x ULN; Bilirubin ≤ 2.0 mg/dl
No chronic lung diseases, such as obstructive pulmonary disease or bronchial asthma, required continuous medications without respiratory failure (SpO2 oxygen saturation > 92% at room temperature).
No arrhythmia, no intracardiac thrombus or vascular wall, no heart failure, LVEF ≥ 45%
Blood test:
Absolute neutrophil count (ANC) ≥ 1,000/mm3 (1 G/l) without filgrastim
Absolute lymphocyte count ≥ 100/mm3 (0.1 G/l)
Absolute platelet count ≥ 75,000/mm3 (75 G/l)
Hemoglobin ≥ 8.0 g/dl
Positive for CD19 measured by immunohistochemistry or flow cytometry.
Agree to participate in the study
Agree to use safe methods of contraception for female patients.

Exclusion criteria:

Involved central nervous system invasion at the time of screening.
Medical history of veno-occlusive disease (VOD).
Required acute treatment due to tumors such as intestinal obstructions, vascular compression, or respiratory failure.
Having active hemolytic anemia.
Diagnosed with primary immunodeficiency.
Medical history of autoimmune neurological diseases or neuromyelitis.
Receiving immunosuppressive medication, except for ≤ 30 mg prednisolone or equivalent at the time of CAR-T-cell transfusion.
Having acute, progressive, or chronic graft-versus-host disease (GvHD).
Having active infectious diseases determined by clinical, imaging, or other laboratory tests (blood culture, PCR, etc.)
Patients who are critically ill or at risk of premature death characterized by:
Acute liver failure requiring dialysis
Heart failure requiring vasopressors
Systemic infection unresponsive to antibiotics
ECOG performance status ≥ 3 points at the time of screening
Having other severe concomitant diseases (e.g., uncontrolled arterial hypertension, heart failure NYHA III-IV).
Unstable angina within 3 months prior to screening.
Any previous or concurrent malignancy was not B-cell lymphoma or B-ALL.
Medical history of clinically relevant central nervous system disease, such as epilepsy, convulsions, paralysis, aphasia, uncontrolled cerebrovascular disease, traumatic brain injury, and Parkinson's disease.
Intolerance to excipients from cellular products.
Pregnant women or those who expect to be pregnant or reastfeeding.
Other diseases or other conditions and circumstances that, according to the investigator's assessment, make it difficult to ensure compliance with study treatment.
Participation in another clinical trial at the time of screening